Envarsus XR and Fluvoxamine Maleate
Determining the interaction of Envarsus XR and Fluvoxamine Maleate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:FluvoxaMINE may increase the blood levels of tacrolimus. In some cases, this can increase the risk of serious side effects such as kidney problems, diabetes, nervous system disorders, hyperkalemia (high potassium levels in the blood), high blood pressure, irregular heart rhythm, heart failure, infections, and various types of malignancies including lymphoma and skin cancer. You may need a dose adjustment if you have been taking tacrolimus and are starting treatment with fluvoxaMINE. Contact your doctor if you develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. Also seek medical attention if you experience frequent urination, increased hunger or thirst, loss of appetite, confusion, tremor, numbness or tingling, seizures, vision changes, sudden dizziness, lightheadedness, fainting, shortness of breath, heart palpitations, and chest pain. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the blood concentrations of the macrolide immunosuppressants sirolimus and tacrolimus, both of which are metabolized by the isoenzyme.
MANAGEMENT: The possibility of prolonged and/or increased pharmacologic effects of macrolide immunosuppressant therapy should be considered, including adverse effects such as fever, infection, diarrhea, hypokalemia, anemia, thrombocytopenia, leukopenia, and hyperlipidemia. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.
- "Product Information. Parlodel (bromocriptine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
- "Product Information. Prograf (tacrolimus)." Fujisawa, Deerfield, IL.
- "Product Information. Rapamune (sirolimus)" Wyeth-Ayerst Laboratories, Philadelphia, PA.
- Christians U, Schmidt G, Bader A, et al "Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes." Br J Clin Pharmacol 41 (1996): 187-90
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: tacrolimus
Brand name: Envarsus XR, Astagraf XL, Prograf, Hecoria
Synonyms: n.a.
Generic Name: fluvoxamine
Brand name: Luvox, Luvox CR
Synonyms: Fluvoxamine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Envarsus XR-Fluvoxamine Tablets
- Envarsus XR-Fluxid
- Envarsus XR-Fluzone
- Envarsus XR-Fluzone 2013-2014 Formula
- Envarsus XR-Fluzone 2015-2016 Formula
- Envarsus XR-Fluzone High Dose 2015-2016 Formula
- Fluvoxamine Maleate-Enzalutamide
- Fluvoxamine Maleate-Enzoclear Foam
- Fluvoxamine Maleate-Eolarix
- Fluvoxamine Maleate-Eovist
- Fluvoxamine Maleate-Epaned
- Fluvoxamine Maleate-Epanova